News

Cohance Lifesciences announced that the 8th Annual General Meeting(AGM) of the company will be held on 17 September 2026.

Net loss of Cohance Lifesciences reported to Rs 24.12 crore in the quarter ended June 2026 as against net profit of Rs 48.88 crore during the previous quarter ended June 2025. Sales declined 23.13% to Rs 422.26 crore in the quarter ended June 2026 as against Rs 549.31 crore during the previous quarter ended June 2025. ParticularsQuarter EndedJun. 2026Jun. 2025% Var. Sales422.26549.31 -23 OPM %0.2720.39 - PBDT6.67116.00 -94 PBT-42.8770.86 PL NP-24.1248.88 PL Powered by Capital Market - Live News

Cohance Lifesciences will hold a meeting of the Board of Directors of the Company on 5 August 2026.

Net profit of Cohance Lifesciences declined 83.77% to Rs 19.55 crore in the quarter ended March 2026 as against Rs 120.43 crore during the previous quarter ended March 2025. Sales declined 26.33% to Rs 619.12 crore in the quarter ended March 2026 as against Rs 840.42 crore during the previous quarter ended March 2025.For the full year,net profit declined 63.22% to Rs 179.23 crore in the year ended March 2026 as against Rs 487.34 crore during the previous year ended March 2025. Sales declined 13.03% to Rs 2268.55 crore in the year ended March 2026 as against Rs 2608.50 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales619.12840.42 -26 2268.552608.50 -13 OPM %15.9427.27 -18.8230.56 - PBDT87.65230.82 -62 423.84825.21 -49 PBT36.42176.65 -79 236.51658.41 -64 NP19.55120.43 -84 179.23487.34 -63 Powered by Capital Market - Live News

Cohance Lifesciences will hold a meeting of the Board of Directors of the Company on 12 May 2026.